Medicaid Pays Millions in Excess Costs Due to Delayed Generic Drug Entry

Among the 69 brand-name drugs that were expected to lose market exclusivity between 2010 and 2015, only 38 products saw the launch of generic versions either before or within one quarter of the expected date, according to a recent study published in Health Affairs. For the 31 drugs whose generic entry was delayed by more than one quarter or did not occur, Medicaid incurred additional associated costs of $760.7 million between 2010 and 2016.

© 2023 MMIT
Jinghong Chen

Jinghong Chen Reporter

Jinghong produces infographics and data stories on health insurance and specialty pharmacy for AIS Health. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting. Before joining AIS in 2018, she worked at WBEZ, Al Jazeera English and The New York Times Chinese.

Related Posts

bills-and-pills
January 26

Medicare Enrollees May Still Face Affordability Issues After Part D Benefit Redesign

READ MORE
pills-in-hand
January 26

ICER Report Aims to Nudge Payers Toward Fairer Drug Coverage Policies

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
January 26

News Briefs: Lilly Alzheimer’s Drug Fails to Win Accelerated Approval

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today